CMC(SH:603122) Xuan Gu Bao·2025-11-13 12:22Group 1: Suspension and Restructuring - Hualan Group is planning a change in company control, leading to a suspension of its stock [1] Group 2: Mergers and Acquisitions - Lideman intends to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan. Xiansheng Xiangrui specializes in in vitro diagnostic reagents and human vaccines, with key products including tuberculin purified protein derivative and BCG purified protein derivative, primarily used in tuberculosis screening, diagnosis, treatment, and innovative vaccine development [2] Group 3: Investment Cooperation and Operational Status - Tianqi Co., Ltd. expects to complete the construction of a robot production line in the first quarter of 2026, gradually forming production capacity [3] - Tianli Lithium Energy has obtained a patent for lithium-ion battery positive electrode sheets and their preparation methods [4] - Yunnan Ge Industry anticipates reaching an annual production capacity of 1.25 million pieces of germanium chips by the end of 2025 [5] - Lichung Group's subsidiary has secured a project worth 1.135 billion yuan [5] - Fospower Technology plans to establish a project company with related parties to invest in the construction of a pilot platform project for battery-grade lithium sulfide [5] - Cambridge Technology's 1.6T optical module product testing data is comparable to leading industry players, with some products already entering small batch supply [5] - Aisen Co., Ltd. will next test KrF photoresist at leading wafer fabs [5] Group 4: Performance Changes - SMIC reported a net profit of 1.517 billion yuan for the third quarter, representing a year-on-year increase of 43.1% [6]